GlassScriptPhysician profile
Hend F Andrew
NPI 1366456881
$5,672.49
in general payments reported to CMS, 2019-2025
35 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $1,033 · 2021: $1,213 · 2022: $53.55 · 2023: $176 · 2024: $809 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,647.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $745.85 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $733.26 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $451.68 | 2019-2025 | |
| Glaxosmithkline, LLC. | $436.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $416.91 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $409.33 | 2020-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.46 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $305.07 | 2019-2021 | |
| Amarin Pharma, INC. | $200.72 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $186.51 | 2019-2024 | Spravato |
| Abbvie INC. | $159.26 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.17 | 2020-2025 | Xifaxan |
| Exact Sciences Corporation | $135.52 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $95.33 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $83.50 | 2025 | Austedo Xr |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $81.56 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $80.46 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $65.26 | 2025 | |
| Daiichi Sankyo INC. | $64.20 | 2019-2020 | |
| Phadia US INC. | $57.90 | 2022-2024 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $57.88 | 2021-2025 | |
| Abbott Laboratories | $57.15 | 2020-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $45.49 | 2025 | Voquezna |
| Eisai INC. | $45.07 | 2021 | |
| Avanir Pharmaceuticals, INC. | $43.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.59 | 2021-2022 | |
| Axsome Therapeutics, INC. | $33.28 | 2025 | Auvelity |
| Astellas Pharma US INC | $31.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $30.67 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $23.04 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.66 | 2021 | |
| Bioventus LLC | $19.42 | 2021 | |
| Si-Bone, INC. | $19.17 | 2025 | |
| Dexcom, INC. | $18.19 | 2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $15.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hend Andrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.